Prosonix Elects Dr Ken Cunningham to its Board of Directors Adding Significant Experience in Respiratory Drug Development
Prosonix, an emerging pharmaceutical company developing a portfolio of enhanced respiratory medicines enabled by its novel proprietary particle engineering technology, announced that it has elected Dr Ken Cunningham to its Board of Directors as a Non-Executive Director and Chair of its Advisory Board.
Dr Cunningham has over 20 years' experience in the pharmaceutical industry with a strong focus in recent years on respiratory drug development and drug delivery. He is Executive Chairman of PolyTherics Ltd and until August 2010 was CEO of Skyepharma plc. Before that he was Chief Executive Officer of Arakis Ltd, Vice-President European Affairs at Alza Corporation and Vice-President Clinical Development at Sequus Inc. Prior to this he held a variety of clinical development and commercial strategy roles at GlaxoWellcome plc and Warner-Lambert earlier in his career. Ken is also a Non-Executive Director of Xention Ltd. He holds a medical degree from St Mary's, Imperial College, London University.
Other news from the department people
